Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
Article
PubMed
Google Scholar
Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11(8):558–72.
Article
CAS
PubMed
Google Scholar
Theegarten D, Hager T. Pathology of lung cancer. Radiologe. 2016;56(9):777–85.
Article
CAS
PubMed
Google Scholar
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.
Article
CAS
PubMed
Google Scholar
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311.
Article
CAS
PubMed
Google Scholar
Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, et al. Scientific advances in lung cancer 2015. J Thorac Oncol. 2016;11(5):613–38.
Article
PubMed
Google Scholar
Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93–115.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005;23(36):9408–21.
Article
CAS
PubMed
Google Scholar
Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266(5192):1821–8.
Article
CAS
PubMed
Google Scholar
Tamakawa RA, Fleisig HB, Wong JM. Telomerase inhibition potentiates the effects of genotoxic agents in breast and colorectal cancer cells in a cell cycle-specific manner. Cancer Res. 2010;70(21):8684–94.
Article
CAS
PubMed
Google Scholar
Senese S, Lo YC, Huang D, Zangle TA, Gholkar AA, Robert L, et al. Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development. Cell Death Dis. 2014;5:e1462.
Article
CAS
PubMed
PubMed Central
Google Scholar
Manchado E, Guillamot M, Malumbres M. Killing cells by targeting mitosis. Cell Death Differ. 2012;19(3):369–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen-Zion M, Lilling G, Beitner R. The dual effects of Ca2 + on binding of the glycolytic enzymes, phosphofructokinase and aldolase, to muscle cytoskeleton. Biochem Med Metab Biol. 1993;49(2):173–81.
Article
CAS
PubMed
Google Scholar
Hu H, Juvekar A, Lyssiotis CA, Lien EC, Albeck JG, Oh D, et al. Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton. Cell. 2016;164(3):433–46.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mukai T, Joh K, Arai Y, Yatsuki H, Hori K. Tissue-specific expression of rat aldolase A mRNAs. Three molecular species differing only in the 5′-terminal sequences. J Biol Chem. 1986;261(7):3347–54.
CAS
PubMed
Google Scholar
Ji S, Zhang B, Liu J, Qin Y, Liang C, Shi S, et al. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Lett. 2016;374(1):127–35.
Article
CAS
PubMed
Google Scholar
Shimizu T, Inoue K, Hachiya H, Shibuya N, Shimoda M, Kubota K. Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas. J Gastroenterol. 2014;49(9):1324–32.
Article
CAS
PubMed
Google Scholar
Kawai K, Uemura M, Munakata K, Takahashi H, Haraguchi N, Nishimura J, et al. Fructose-bisphosphate aldolase A is a key regulator of hypoxic adaptation in colorectal cancer cells and involved in treatment resistance and poor prognosis. Int J Oncol. 2017;50(2):525–34.
Article
CAS
PubMed
Google Scholar
Du S, Guan Z, Hao L, Song Y, Wang L, Gong L, et al. Fructose-bisphosphate aldolase a is a potential metastasis-associated marker of lung squamous cell carcinoma and promotes lung cell tumorigenesis and migration. PLoS ONE. 2014;9(1):e85804.
Article
PubMed
PubMed Central
Google Scholar
Chang YC, Chan YC, Chang WM, Lin YF, Yang CJ, Su CY, et al. Feedback regulation of ALDOA activates the HIF-1 alpha/MMP9 axis to promote lung cancer progression. Cancer Lett. 2017;403:28–36.
Article
CAS
PubMed
Google Scholar
Sasaki K, Murakami T, Kawasaki M, Takahashi M. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol. 1987;133(3):579–84.
Article
CAS
PubMed
Google Scholar
Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23(28):7212–20.
Article
CAS
PubMed
Google Scholar
Warth A, Cortis J, Soltermann A, Meister M, Budczies J, Stenzinger A, et al. Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer. 2014;111(6):1222–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vasquez RJ, Howell B, Yvon AM, Wadsworth P, Cassimeris L. Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. Mol Biol Cell. 1997;8(6):973–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–23.
Article
CAS
PubMed
Google Scholar
Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer. 2008;8(9):714–24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8(9):671–82.
Article
CAS
PubMed
Google Scholar
Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012;22(4):438–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang LQ, Jiang F, Xu L, Wang J, Bai JL, Yin R, et al. The role of cyclin D1 expression and patient’s survival in non-small-cell lung cancer: a systematic review with meta-analysis. Clin Lung Cancer. 2012;13(3):188–95.
Article
CAS
PubMed
Google Scholar
Massague J. G1 cell-cycle control and cancer. Nature. 2004;432(7015):298–306.
Article
CAS
PubMed
Google Scholar
Sobell HM. Actinomycin and DNA transcription. Proc Natl Acad Sci USA. 1985;82(16):5328–31.
Article
CAS
PubMed
PubMed Central
Google Scholar
Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci. 2008;121(Pt 23):3853–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90.
Article
CAS
PubMed
Google Scholar
Juergens RA, Bratman SV, Tsao MS, Laurie SA, Sara Kuruvilla M, Razak AR, et al. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. Cancer Treat Rev. 2017;54:43–57.
Article
CAS
PubMed
Google Scholar
Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911–2.
Article
CAS
PubMed
Google Scholar
Warburg O. The metabolism of carcinoma cells. J Cancer Res. 1925;9:148–63.
Article
CAS
Google Scholar
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.
Article
CAS
PubMed
Google Scholar
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
Article
CAS
PubMed
Google Scholar
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–64.
Article
CAS
PubMed
Google Scholar
Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17(4):351–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Luo W, Semenza GL. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab. 2012;23(11):560–6.
Article
PubMed
PubMed Central
Google Scholar
Sun H, Zhu A, Zhang L, Zhang J, Zhong Z, Wang F. Knockdown of PKM2 suppresses tumor growth and invasion in lung adenocarcinoma. Int J Mol Sci. 2015;16(10):24574–87.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 2011;480(7375):118–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012;150(4):685–96.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev. 2013;2:10.
Article
PubMed
PubMed Central
Google Scholar
Zhang F, Lin JD, Zuo XY, Zhuang YX, Hong CQ, Zhang GJ, et al. Elevated transcriptional levels of aldolase A (ALDOA) associates with cell cycle-related genes in patients with NSCLC and several solid tumors. BioData Min. 2017;10:6.
Article
PubMed
PubMed Central
Google Scholar
Ritterson Lew C, Tolan DR. Targeting of several glycolytic enzymes using RNA interference reveals aldolase affects cancer cell proliferation through a non-glycolytic mechanism. J Biol Chem. 2012;287(51):42554–63.
Article
CAS
PubMed
Google Scholar
Mamczur P, Gamian A, Kolodziej J, Dziegiel P, Rakus D. Nuclear localization of aldolase A correlates with cell proliferation. Biochim Biophys Acta. 2013;1833(12):2812–22.
Article
CAS
PubMed
Google Scholar
Ma D, Chen X, Zhang PY, Zhang H, Wei LJ, Hu S, et al. Upregulation of the ALDOA/DNA-PK/p53 pathway by dietary restriction suppresses tumor growth. Oncogene. 2018;37(8):1041–8.
Article
CAS
PubMed
Google Scholar
Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremnes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21(20):3798–807.
Article
CAS
PubMed
Google Scholar
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16.
Article
CAS
PubMed
Google Scholar
Laurie SA, Goss GD. Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J Clin Oncol. 2013;31(8):1061–9.
Article
CAS
PubMed
Google Scholar
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.
Article
CAS
PubMed
Google Scholar
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.
Article
CAS
PubMed
Google Scholar
Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528–38.
Article
CAS
PubMed
Google Scholar
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–92.
Article
CAS
PubMed
Google Scholar
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.
Article
CAS
PubMed
Google Scholar
Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525–31.
Article
CAS
PubMed
Google Scholar
Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne PA, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006;24(33):5253–8.
Article
CAS
PubMed
Google Scholar
Gomes JR, Cruz MRS. Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors. Oncotargets Ther. 2015;8:1137–42.
Article
CAS
Google Scholar
Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, et al. Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors. Cancer Res. 2017;77(8):2078–89.
Article
CAS
PubMed
Google Scholar
Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73(5):1524–35.
Article
CAS
PubMed
PubMed Central
Google Scholar
Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513(7519):559–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 2011;14(4):443–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lim S, Liu H, Madeira da Silva L, Arora R, Liu Z, Phillips JB, et al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1alpha. Cancer Res. 2016;76(8):2231–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab. 2012;16(1):9–17.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu XS, Little JB, Yuan ZM. Glycolytic metabolism influences global chromatin structure. Oncotarget. 2015;6(6):4214–25.
PubMed
PubMed Central
Google Scholar
Kong XJ, Kuilman T, Shahrabi A, Oshuizen JB, Kemper K, Song JY, et al. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature. 2017;550(7675):270–4.
Article
PubMed
PubMed Central
Google Scholar